NASDAQ:SLRN Acelyrin (SLRN) Stock Price, News & Analysis $4.47 +0.04 (+0.90%) (As of 12:00 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Acelyrin Stock (NASDAQ:SLRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acelyrin alerts:Sign Up Key Stats Today's Range$4.26▼$4.5050-Day Range$4.31▼$6.4852-Week Range$3.36▼$8.89Volume120,175 shsAverage Volume1.02 million shsMarket Capitalization$448.48 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company OverviewAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Read More… “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Acelyrin Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks68th Percentile Overall ScoreSLRN MarketRank™: Acelyrin scored higher than 68% of companies evaluated by MarketBeat, and ranked 350th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAcelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAcelyrin has only been the subject of 2 research reports in the past 90 days.Read more about Acelyrin's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acelyrin are expected to grow in the coming year, from ($2.57) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acelyrin is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acelyrin is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcelyrin has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.33% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Acelyrin has recently decreased by 8.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcelyrin does not currently pay a dividend.Dividend GrowthAcelyrin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.33% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Acelyrin has recently decreased by 8.91%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.08 News SentimentAcelyrin has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Acelyrin this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acelyrin insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acelyrin's insider trading history. Receive SLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter. Email Address SLRN Stock News HeadlinesUCB gets FDA approval for Bimzelx for hidradenitis suppurativaNovember 20 at 6:16 PM | msn.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Acelyrin, Inc. (SLRN) and Encourages Long-Term SLRN Investors to Contact the FirmNovember 19 at 11:00 PM | markets.businessinsider.comMan behind OpenAI makes shocking new betBillionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.November 21, 2024 | DTI (Ad)HC Wainwright Increases Earnings Estimates for AcelyrinNovember 18 at 1:30 AM | americanbankingnews.comVikram Purohit’s Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock MovementNovember 15, 2024 | markets.businessinsider.comStrategic Shifts and Promising Developments Drive ACELYRIN’s Potential Share DoublingNovember 14, 2024 | markets.businessinsider.comAcelyrin’s Phase 3 Trial Progress and Uncertainties Lead to Hold RatingNovember 14, 2024 | markets.businessinsider.comACELYRIN, INC. Receives Buy Rating from Tyler Van Buren Due to Clinical Progress and Strategic AdvancementsNovember 14, 2024 | markets.businessinsider.comSee More Headlines SLRN Stock Analysis - Frequently Asked Questions How have SLRN shares performed this year? Acelyrin's stock was trading at $7.46 at the beginning of the year. Since then, SLRN stock has decreased by 39.9% and is now trading at $4.48. View the best growth stocks for 2024 here. How were Acelyrin's earnings last quarter? Acelyrin, Inc. (NASDAQ:SLRN) posted its earnings results on Tuesday, August, 13th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.08. When did Acelyrin IPO? Acelyrin (SLRN) raised $540 million in an IPO on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share. Who are Acelyrin's major shareholders? Top institutional investors of Acelyrin include Geode Capital Management LLC (1.65%), Jacobs Levy Equity Management Inc. (1.33%), State Street Corp (1.28%) and Ikarian Capital LLC (0.68%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston. View institutional ownership trends. How do I buy shares of Acelyrin? Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Acelyrin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX). Company Calendar Last Earnings8/13/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLRN CUSIPN/A CIK1962918 Webwww.acelyrin.com Phone805-730-0360FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$20.00 Low Stock Price Target$6.00 Potential Upside/Downside+159.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-381,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.12% Return on Assets-39.02% Debt Debt-to-Equity RatioN/A Current Ratio7.15 Quick Ratio7.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.74 per share Price / Book0.66Miscellaneous Outstanding Shares100,330,000Free Float86,682,000Market Cap$444.46 million OptionableOptionable Beta1.98 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:SLRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.